Aurobindo Pharma shares fall 3% after Q2 earnings

New Delhi: Shares of Aurobindo Pharma Tuesday fell almost 3 per cent after the company reported 21.70 per cent dip in consolidated net profit for the quarter ended September 30, 2018. The stock went down 2.96 per cent to end at Rs 774.70 on BSE. During the day, it declined 4.76 per cent to Rs 760.25.

On NSE, shares of the company dropped 2.63 per cent to close at Rs 775.

Aurobindo Pharma Monday reported 21.70 per cent dip in consolidated net profit to Rs 611.44 crore for the September quarter, mainly on account of rise in expenses.

The company had posted a net profit of Rs 780.97 crore in the year-ago period, Aurobindo Pharma said in a BSE filing.

Consolidated total revenue from operations stood at Rs 4,751.40 crore for the quarter under review. It was Rs 4,435.89 crore in the same period last year.

Total expenses stood at Rs 3,964.20 crore for the reported quarter. It was Rs 3,468.36 crore during the same period of 2017-18.

  • Related Posts

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Puresta launches EVERQ, AI-powered skin-health platform

    Puresta launches EVERQ, AI-powered skin-health platform

    Stem cell therapy for autism only in approved clinical trials: Centre

    Stem cell therapy for autism only in approved clinical trials: Centre